Evaxion Biotech A/S - ADR
EVAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.27M
Close$
$-0.33
108.6% downside
Current Fair Value
108.6% downsideOvervalued by 108.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.27 Million |
|---|---|
| Enterprise Value | $9.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.21 |
| Beta | 0.27 |
| Outstanding Shares | 8,340,215 |
Return
| Return on Equity | -57.48% |
|---|---|
| Return on Assets | -34.47% |
| Return on Invested Capital | -48.53% |
Valuation & Multiples
| P/E Ratio | -3.41 |
|---|---|
| PEG | -2.61 |
| Price to Sales | - |
| Price to Book Ratio | 1.94 |
| Enterprise Value to Revenue | 1.26 |
| Enterprise Value to EBIT | -0.81 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.79 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 26, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$9.20 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$6.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.94%▲ 0.60% |
|---|---|
| Total Invested | $1.22M▲ 19.57% |
| Investors Holding | 15▲ 2.00% |
ESG Score
No data
About Evaxion Biotech A/S
2,020 employeesEvaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immu...